Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

iScience

Topics

Medicine

Immunology

Internal Medicine

Neurology

Infectious Diseases

Show all topics

DOI

10.1016/j.isci.2023.106124

License

CC-BY-NC-ND

Other Formats

PDF